contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


remedy-extensive-report-leveling-requires-more-patient-play

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Atte Riikola

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Insider purchases have been made. The homegrown feel has been broken, and an international CEO has been recruited. Former Chairman and principal owner Mäki showed humility regarding the board’s mistakes in the Inderes quarterly interview. “Service-model games” were removed from the “Commercial Models” page in the 2025 annual report. One cannot be satisfied with the performance of recent years, but it seems that the company has understood the need to press the reset button. Now, if Resonant turns out to be such a good game (commercially!), then in addition to a certain famous fictional writer, long-term Remedy investors will also be saved from the ‘Dark Place’.

Now this latest Dev Diary has been released. It reveals more gameplay and looks good. Bigger investments in this area. It has allowed for more enemy types, weapons, and features.

A little Easter surprise there. It would indeed be great if these were purchased with personal funds, as the announcements seem to indicate. A good signal from the new CEO, and generally, I consider it standard practice for a public company’s CEO to be committed through share ownership in one way or another. I’m also not at all worried about the CEO’s “EA” background, because in my opinion, it has always been clear that he was not hired to “monetize” Remedy’s games, but perhaps to help the games globalize (especially in Asia?). The only exception to this could have been FBC, which, with greater success, could have offered a platform for microtransactions and the like, but a CEO is hardly hired for one game, especially since FBC is somewhat off the main track of Remedy’s core, which is the AW/Control pipeline. As a side note, if the CEO has put 60 hours into Control Resonant, one would assume the product is in good shape  Many hints have already dropped from Remedy’s side, and that April Fools’ “Release date” joke was excellent, but nothing majorly new yet. Somehow, considering all this activity, it would seem distant if the launch were only after the summer holidays, but with current information, there’s nothing to do but wait and wonder.

At first glance, these seem to be shares bought with their own money. They appeared twice in Kauppalehti, 4128 shares for the CEO and 890 shares for Kallionpää:                   Tärkeimmät talousuutiset | Kauppalehti – 2 Apr 26              Remedy Entertainment Plc: Managers' Transactions ­– Jean-Charles Gaudechon    Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä.                                               Tärkeimmät talousuutiset | Kauppalehti – 2 Apr 26              Remedy Entertainment Plc: Managers' Transactions ­– Santtu Kallionpää    Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä.

They’re taking a bit of a risk with this April Fool’s joke, aren’t they?  “Dates behind bars” = release date. I’m guessing most people will miss it, and the disappointment could be big if/when no release date is given soon. On the other hand, Remedy’s “official” April Fool’s joke seemed to be Alan Wake 2 dubbed in Finnish:

Yesterday, I met with Remedy’s new CEO, primarily to explain how our Hesuli works and what investors currently think about Remedy. Overall, I came away with a very positive first impression. JC is clearly a passionate gamer and had reportedly spent 60 hours testing Control Resonant during his first month. He clearly wants to stay closely involved with the game development teams in the future. The concerns raised here and among gamers in general about his EA background when he was appointed CEO can, in my opinion, be forgotten. We didn’t talk about multiplayer or microtransactions  But let’s let the man himself share more of his thoughts in the Q1 earnings interview.

Remedy Entertainment

Remedy is now building the next growth leap of its strategy with the 5 major game projects under development. This will be reflected in rising costs between 2022 and 2023, but enable significant earnings growth particularly in 2025-2026, driven by increasing royalty income. 

<p>Remedy is now building the next growth leap of its strategy with the 5 major game projects under development. This will be reflected in rising costs between 2022 and 2023, but enable significant earnings growth particularly in 2025-2026, driven by increasing royalty income. In terms of long-term growth potential, we see the share's risk/return ratio as attractive, but with our lowered forecasts, this will take longer to materialize than previously expected. Thus, in the short term, the attractiveness of the stock has weakened compared to our previous estimates. </p> 

	2021	22e	23e
Revenue	44.7	48.1	46.6
growth-%	8.9 %	7.4 %	-3.0 %
EBIT (adj.)	11.4	6.7	0.6
EBIT-% (adj.)	25.5 %	13.9 %	1.4 %
EPS (adj.)	0.67	0.39	0.03
Dividend	0.17	0.17	0.17
Dividend %	0.4 %	1.4 %	1.4 %
P/E (adj.)	59.0	31.2	382.0
EV/EBITDA	33.0	13.1	35.3

Remedy (Extensive Report): Leveling up requires more patient play

Key Estimate Figures02.06.2022

Forum discussions